Denka Selected as a "Most Liked!" IR Award Winner in the 2023 IR Award

FY2023 Second Quarter Financial Results Presentation Summary of Q&A Session

FY2023 Second Quarter Financial Results Presentation Materials

FY2023 Second Quarter Summary of Consolidated Financial Statements

FY2023 First Quarter Financial Results Presentation Summary of Q&A Session

FY2023 First Quarter Financial Results Presentation Materials

FY2023 First Quarter Summary of Consolidated Financial Statements

Notice of Convocation of the 164th Ordinary General Meeting of Shareholders Other Matters Subject to the Electronic Provision

Notice of Convocation of the 164th Ordinary General Meeting of Shareholders

FY2022 Financial Results Presentation Summary of Q&A Session

FY2022 Financial Results Presentation Topics (Launch of Mission 2030 Management Plan and Growth Strategy for Silicon Nitride and G47Δ, Oncolytic Herpes Virus)

FY2022 Financial Results Presentation Materials

FY2022 Summary of Consolidated Financial Statements

FY2022 Third Quarter Financial Results Presentation Summary of Q&A Session

FY2022 Third Quarter Financial Results Presentation Materials

Notice Regarding Personnel Changes in Representative Directors and Executive Officers

FY2022 Third Quarter Summary of Consolidated Financial Statements

U.S. EPA’s Review of the Toxicity Assessment of Chloroprene Monomers (7th Report) – Lawsuit Filed Against EPA for Correction of Toxicity Assessment Based on Latest Science –

Notice Regarding Revisions to Consolidated Financial Results Forecast and Year-end Dividend Forecast for the Fiscal Year Ending March 31, 2023